← All trials
NCT05940428
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 1, 2025
- First posted
- Jul 11, 2023
- Last posted
- Jul 14, 2023
- Enrollment
- 26
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AskGene Pharma, Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Suzhou Aosaikang Biopharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.